For more information or confidential assistance
800-306-3180
se habla español

Invokana Lawsuit Alleges Drug Caused Urosepsis

Severe side effects of Invokana – part of a new class of diabetes drugs manufactured by J&J – have prompted a wave of litigation filed throughout the United States. Most of the Invokana lawsuits have been centralized in New Jersey federal court under MDL # 2750 for more efficient pretrial... Read more »

Federal Farxiga Lawsuits Consolidated in NY

The makers of Farxiga, Bristol-Myers Squibb and AstraZeneca, are facing at least 18 product liability lawsuits filed in federal courts. These have now been centralized into a multidistrict litigation (MDL) pursuant to an order issued by the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued on April 6, 2017. The... Read more »

First Steps Commence in Invokana Litigation

Antidepressant Lawsuit
In mid-January, the first steps in the Invokana multidistrict litigation (MDL) began. U.S. District Judge Brian Martinotti, who is presiding over the MDL in the District of New Jersey, announced 1) the pending appointment of a special mediator to deal with discovery issues and settlement possibilities and 2) a “science... Read more »

FDA Invokana Study Finds Potential Amputation Link

FDA
The U.S. Food and Drug Administration has issued a new safety alert regarding the type 2 diabetes drug canagliflozin — Invokana and Invokamet. The Agency issued a safety announcement on May 18, notifying patients and the medical community that results of an ongoing clinical trial revealed a higher number of... Read more »

Report Highlights Risks of Newer Diabetes Drugs

Metabolic acidosis is a risk associated with Invokana that was recently highlighted in a report by the Institute for Safe Medical Practices (ISMP). Invokana is one of the drugs recently touted for its ability to manage type 2 diabetes, but potential side effects have raised concerns and led to a... Read more »

Invokana Lawsuit Filed in Alabama District Court

The drug Invokana belongs to a class of Type II diabetes medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, and is referred to generically as canagliflozin. This class of drugs, which also includes well-known brands like Farxiga, Xigdua XR, Jardiance and Glyxambi, was once highly-touted as an innovative alternative for Type II... Read more »

FDA Issues Warning about SGLT2 inhibitor Side Effects

The FDA has issued a safety communication involving potentially dangerous side effects associated with a category of type 2 diabetes drugs known as SGLT2 inhibitors. The agency has warned that use of the drug could lead to ketoacidosis, a serious condition often requiring emergency medical care. Urinary tract infections or... Read more »

Lawsuit Alleges Kidney Damage after Invokana Use

A plaintiff who recently filed a lawsuit against Invokana manufacturers Janssen Pharmaceuticals and Johnson & Johnson claims use of the drug to treat type 1 diabetes led to serious kidney damage. The lawsuit further accuses the companies of failing to warn consumers and the medical community about the risk associated with... Read more »